Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2021

View Archived Issues

Targeting the NOX1-IL-6-secretory phenotype proinflammatory signaling axis can ease cell senescence

Engineered Salmonella for intracellular delivery of protein drugs to solid tumors

Researchers recapitulate anti-NMDA receptor encephalitis in zebrafish

FD-223, a novel PI3Kdelta inhibitor with potent activity in models of AML

Ndufv2 as a sex-specific genetic factor influencing mitochondrial functions

Almirall patents new TYK2 inhibitors

GWAS meta-analysis identifies genetic variants linked to vertigo

Mitobridge discloses new CD38 inhibitors

Disarm Therapeutics discloses SARM1 inhibitors

Cocrystal Pharma presents new antiviral compounds

iTeos Belgium describes new ENT1 inhibitors

RM-1490, a novel MOR agonist as maintenance therapeutic in opioid use disorder

Imugene and Eureka collaborate to evaluate oncolytic virus and T-cell therapy for solid tumors

APTA-1 shows promise in coronavirus-induced acute lung injury model

Mosaic ImmunoEngineering presents structural details on cowpea mosaic virus

Studies link GRP78 to severe COVID-19 in older and obese diabetic patients

High blood LPE(20:4) levels tied to migraine

Moderna and Metagenomi collaborate to advance in vivo gene editing therapeutics

Studies show that psoriasis is more than skin-deep

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...